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Abstract
Folliculo-stellate cells are a nonendocrine, sustentacular-like complementary population of the
anterior pituitary. They currently are considered as functionally and phenotypically heterogeneous,
with one subpopulation of folliculo-stellate cells possibly representing resident adenohypophyseal
macrophages. We took advantage of a limited T-cell mediated inflammatory reaction selectively
involving tumor tissue in three cases of pituitary adenoma (2 prolactin cell adenomas, and 1 null
cell adenoma) to test the hypothesis whether some folliculo-stellate cells within inflammatory foci
would also assume monocytic/dendritic properties. Immunohistochemical double labeling for S-100
protein and the class II major histocompatibility antigen HLA-DR indeed showed several arborized
cells to coexpress both epitopes. These were distributed both amidst adenomatous acini and along
intratumoral vessels, and were morphologically undistinguishable from conventional folliculo-
stellate cells. On the other hand, markers of follicular dendritic cells (CD21) and Langerhans' cells
(CD1a) tested negative. Furthermore, no S-100/HLA-DR coexpressing folliculo-stellate cells were
seen in either peritumoral parenchyma of the cases in point nor in control pituitary adenomas
lacking inflammatory reaction. These findings suggest that a subset of folliculo-stellate cells may be
induced by an appropriate local inflammatory microenvironment to assume a dendritic cell-like
immunophenotype recognizable by their coexpression of S-100 protein and HLA-DR. By analogy
with HLA-DR expressing cells in well-established extrapituitary inflammatory constellations, we
speculate that folliculo-stellate cells with such immunophenotype may actually perform professional
antigen presentation. A distinctly uncommon finding in pituitary adenomas, lymphocytic infiltrates
may therefore be read as a manifestation of tumoral immunosurveillance.
Background
Folliculo-stellate cells (FSCs) are primarily non-hormone
secreting accessory elements contributing some 5–10% of
cells of the anterior pituitary where they both commingle
and functionally interact with the endocrine population
proper [1].
Recent evidence has been involving FSCs with facets of
adenohypophyseal machinery as manifold as paracrine
regulation, cellular turnover, and neuro-immune cross-
talk [2-4]. Accordingly, the eponymous arborized mor-
phology of FSCs is becoming but a descriptive umbrella
for interstitial cells to be subsumed under, the functions,
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respective immunophenotypes and indeed histogenesis
of which are felt to be nothing less than uniform. Of late,
FSCs have been postulated to descend from a common
neuro-hematopoietic precursor to eventually diversify
along one of three lineages: i.e., "classical/epithelial cell-
like"; "classical/astrocyte-like"; and "true dendritic cell-
like" [1]. While immunopositivity for S-100 protein is
shared by all three derivatives, specific commitment to
either epithelial, glial or monocytic/dendritic properties
has been shown to entail alternative coexpression of
cytokeratin(s), glial fibrillary acidic protein (GFAP), and
MHC class II surface antigens, respectively. Several aspects
of the glial-epithelial avatars of FSCs have been docu-
mented in the context of adenohypophyseal cell cycle – in
particular by pioneering observations by Horvath and
Kovacs on both nonneoplastic and adenomatous human
pituitaries [4,5]. Conversely, data regarding the "true den-
dritic cell-like" (DC) subset of FSCs, as defined above, are
largely restricted to nontumorous human autopsy mate-
rial and transplantation experiments in mice [6,7].
Findings
Our group has recently described a pituitary prolactinoma
(index Case 1) with selective intratumoral infiltration by
T lymphocytes, a phenomenon not documented previ-
ously [8-10]. This constellation has been interpreted as
being consistent with a forme fruste of tumor immunosur-
veillance [11]. In an effort for that serendipitous finding
to be addressed in a systematic context, a further fifty con-
secutive unselected adenomectomy specimens were
screened for the presence of inflammatory infiltrates. Two
additional occurrences – a sparsely granulated prolactin
cell adenoma from a 31-year-old female (Case 2) and a
gonadotroph cell adenoma of oncocytic type from a 67-
year-old male (Case 3) – have been identified. None of
the patients presented evidence of autoimmune endo-
crine disease nor was there clinically or radiologically
detectable sinusitis. Both the morphology and immu-
nophenotype of the intratumoral infiltrates closely paral-
leled those described in index Case 1 [8]: i.e., perivascular
cuffs presided over by T lymphocytes with a predomi-
nance of CD4+ cells that tended to commingle with S-100
protein immunoreactive process bearing cells (Fig. 1a–f).
In addition, a fair number of the latter were scattered
throughout the adenoma tissue. As originally described,
neither ongoing necrosis nor fibrous replacement of the
parenchyma was seen in these examples, either. Conspic-
uously, most – if not all – S-100+ arborized cells also
stained intensely for HLA-DR on immunohistochemical
double labeling (Fig. 1g–k). Yet markers of follicular den-
dritic cells (FDCs) of lymphoid type (CD21) as well as
Langerhans cells (CD1a) tested negative [12]. Further-
more, there was no staining for cytokeratins (MNF-116;
CAM 5.2). While immunoreactivity for GFAP in arborized
cells was largely absent as well, scattered adenomatous
follicles lined by GFAP+ FSCs in Case 2 did also reveal
some staining for HLA-DR (Fig. 1l–n).
We read the present findings as ones suggesting selective
involvement of the DC-like subset of FSCs in tumor
immunosurveillance of pituitary adenomas, in particular
as these fulfill the immunophenotypic criteria set forth by
Allaerts et al [6,11]. Uncommon though this paradigm
obviously is, it is felt to be offering the observational
advantage of a rather restricted inflammatory reaction –
one that may not be forthcoming in conventional lym-
phocytic hypophysitis which tends to involve a higher
degree of vascular permeability as well as necrosis [13]. In
the present setting, FSCs are perceived as ones – at least by
immunophenotypic standards – capable of displaying
tumor-related epitopes in the context of MHC class II anti-
gens for native T lymphocytes. Henceforth, the defining
cellular ingredients of "organized lymphatic tissue" in sec-
ondary lymphoid organs – to which tumoral antigens of
pituitary adenomas are unlikely to gain access – may be
granted a de novo local compartment at which to convene
[11,12].
As to what extent FSCs of DC type actually are to be con-
sidered "professional" antigen presenting cells is, how-
ever, uncertain; especially with respect to their capacity to
prevent apoptosis of selected clones of lymphocytes or
cross-priming – functions routinely performed by FDCs.
Both diagnostic experience with and the natural history of
pituitary adenomas suggest that antitumoral immune
defense eventually falls short of achieving proficient elim-
ination of adenoma cells in most cases.
The findings reported above nevertheless are felt to indi-
cate that (i) pituitary adenomas may not necessarily be
ignored by immune recognition; (ii) immunosurveillance
of pituitary adenomas involves an inflammatory compart-
ment reminiscent of organized lymphoid tissue; and (iii)
a subset of FSCs with DC phenotype are likely to perform
a locum antigen presenting function.
The focal finding in Case 2 of stellate cells expressing HLA-
DR, S-100 protein and GFAP in suggestive association
along adenomatous follicles further raises the question
whether FSCs of DC type are apt to either transdifferenti-
ate into or else being recruited from their "classical/epi-
thelial-like" or "classical/astrocyte-like" counterparts.
Future characterization of the immunoprofile of spindle
cell oncocytoma, a purported FSC neoplasm, may be
expected to yield some insights into this topic [14].
Keeping in mind that a non-negligible part of pituitary
adenomas are not ultimately amenable to cure by either
conventional pharmacotherapy or surgery, exploring the
prospect of immunomodulation may also be of interest inDiagnostic Pathology 2007, 2:20 http://www.diagnosticpathology.org/content/2/1/20
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Microphotographs from Case 3 (a through d) to illustrate basic pattern of inflammatory reaction common to all three adeno- mas in this report: i.e., angiocentric infiltrates of T lymphocytes (b); colonization of tumor interstitium by arborized cells immu- noreactive for S-100 protein (c) and HLA-DR (d), the respective staining patterns of which are felt to be largely overlapping Figure 1
Microphotographs from Case 3 (a through d) to illustrate basic pattern of inflammatory reaction common to all three adeno-
mas in this report: i.e., angiocentric infiltrates of T lymphocytes (b); colonization of tumor interstitium by arborized cells immu-
noreactive for S-100 protein (c) and HLA-DR (d), the respective staining patterns of which are felt to be largely overlapping. 
As exemplified by index Case 1 (e), dendritic cell reaction selectively involves the adenoma compartment (*), while only native 
fibrohistiocytic elements of peritumoral pituitary stain for HLA-DR. Lesional interface is highlighted by dotted line. Conven-
tional gonadotroph cell adenoma from the control series (f) is devoid of S-100+ dendritic cells. Arrows point to activated follic-
ulo-stellate cells in adjacent nontumorous acini to technically validate staining reaction. Overview of double immunostained 
inflammatory focus (g) reveals simultaneous positivity for S-100 protein and HLA-DR in most arborized cells both around 
intratumoral vessel (*) and within interstitium (arrows). Stellate morphology of HLA-DR/S-100 coexpressing cells is appreci-
ated both along vascular sleeves (h and j) of tumoral microcirculation and as these tend to intimately commingle with adenoma 
cells (i and k). In order for reproducibility of specific labeling to be ensured, immunoreactions for both epitopes have been 
duplicated while interverting chromogens. Unique to the prolactin cell adenoma in Case 2 is the finding of adenomatous folli-
cles (l and m) lined in part by HLA-DR immunoreactive FSCs. While rare follicles with nearly identical morphology also did 
stain for GFAP (n), actual coexpression could not be demonstrated. Immunohistochemical specimens depicted in b – d, and m 
– n were developed with horseradish peroxidase and 3,3'-diaminobenzidine; slides shown in e – f, and l are visualized using 
streptavidin-biotin-complex/alkaline phosphatase and new fuchsin-naphtol AS-BI as chromogen. In the double labeling studies 
(g through k), antigen names typeset in either red or black indicate fuchsin-naphtol and diaminobenzidine, respectively. Origi-
nal magnification: a, l through n – ×200; b through f – ×100; g – ×400; h through k – ×1000 (oil immersion).
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two respects. On the one hand, the physiologic potential
of FSCs of DC type to negatively influence adenohypo-
physeal secretion invites to be taken advantage of by phar-
macological induction to inhibit excess hormone
secretion by adenomas [2,3]. On the other hand, a mini-
mal formal framework of cell-mediated antitumoral
defense obviously does emerge in a subset of adenomas.
Converting such jejune inflammatory response into profi-
cient antitumoral defense ought to be elaborated on in the
larger context of tumor immunotherapy. Intriguingly
enough, sporadic empirical reports on beneficial impact
of T lymphocyte stimulation on the evolution of some
pituitary adenomas are on record [15]. Further work ded-
icated to characterization of the inflammatory response in
these tumors seems, therefore, warranted.
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